DS002
DS002 is a human monoclonal antibody targeting NGF/bNGF, with an IC50 of 6.60 nM against human NGF, 1.98 nM against rat NGF, and 8.46 nM against mouse NGF. DS002 blocks NGF-TrkA binding, interrupts pain signal transduction, inhibits TrkA-mediated downstream signaling pathways, and alters aromatic amino acid metabolic pathways. DS002 inhibits cancer cell proliferation. DS002 exerts a preventive effect on Paclitaxel-, Cisplatin- and Vincristine-induced peripheral neuropathy in rats. DS002 can be used in studies related to chronic pain and chemotherapy-induced peripheral neuropathy.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human
|
TrkA |
DS002 potently blocks the binding of human NGF to TrkA in cell-free competitive ELISA assays, with an IC50 of 6.6 nM[2].
DS002 (0.001-100 nM) binds to human, rat and mouse NGF with high affinity in cell-free ELISA assays, with corresponding EC50 values of 0.031 nM, 0.086 nM and 0.036 nM[2].
DS002 (1.5625-100 nM) exhibits ultrahigh binding affinity (KD <1 pM) for human NGF and high binding affinity (KD values of 149 pM and 582 pM, respectively) for rat and mouse NGF in cell-free BLI assays[2].
DS002 potently blocks the binding of rat and mouse NGF to TrkA in cell-free competitive ELISA assays, with IC50 values of 1.98 nM and 8.46 nM, respectively[2].
DS002 inhibits NGF-induced TF-1 cell proliferation in a dose-dependent manner by blocking the TrkA-mediated downstream signaling pathway in cell-based in vitro assays[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
DS002 (0.02-0.5 mg/kg; subcutaneous injection; administered on days -3 to 16) exerts a significant preventive effect against Cisplatin (HY-17394)-induced mechanical hyperalgesia in rats[2].
DS002 (0.5-2.5 mg/kg; subcutaneous injection; administered on days -3 to 3) exerts a significant preventive effect on mechanical and cold allodynia induced by Vincristine (HY-N0488A) in rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (SD) (male, 200-220 g starting weight, paclitaxel-induced CIPN model)[2]
-
Dosage:0.1 mg/kg; 0.5 mg/kg; 2.5 mg/kg
-
Administration:s.c.; administered on days -3, 3, 9
-
Result:Increased paw withdrawal threshold (PWT) significantly compared to vehicle control on day 14.
Decreased acetone-induced pain scores and foot withdrawal frequency drastically compared to vehicle control on day 15 (0.5 mg/kg and 2.5 mg/kg doses).
Caused no weight loss in treated rats.
-
Animal Model:Sprague-Dawley (SD) (male, 200-220 g starting weight, cisplatin-induced CIPN model)[2]
-
Dosage:0.02 mg/kg; 0.5 mg/kg
-
Administration:s.c.; administered on days -3, 3, 9, 16
-
Result:Increased paw withdrawal threshold (PWT) significantly compared to vehicle control on day 21.
Showed no analgesic effect on cold allodynia due to unsuccessful model establishment.
Caused no weight loss in treated rats.
-
Animal Model:Sprague-Dawley (SD) (male, 200-220 g starting weight, vincristine-induced CIPN model)[2]
-
Dosage:0.1 mg/kg; 0.5 mg/kg; 2.5 mg/kg
-
Administration:s.c.; administered on days -3, 3
-
Result:Increased paw withdrawal threshold (PWT) significantly compared to vehicle control on day 7 (0.5 mg/kg and 2.5 mg/kg doses).
Reduced acetone-induced pain scores and foot withdrawal frequency compared to vehicle control on day 8 (0.5 mg/kg and 2.5 mg/kg doses).
Caused no weight loss in treated rats.
NGF/bNGF
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Jin D, et al. Effect of the novel anti-NGF monoclonal antibody DS002 on the metabolomics of pain mediators, cartilage and bone. Front Pharmacol. 2024;15:1396790. Published 2024 Aug 12. [Content Brief]
[2]. Liang ZJ, et al. NGF monoclonal antibody DS002 alleviates chemotherapy-induced peripheral neuropathy in rats. Acta Pharmacol Sin. 2022;43(11):2841-2847. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DS002 Related Classifications
HY-P992345 Related Classifications
Powered by Bioz